Key Takeaways
Moderna Inc. (NASDAQ: MRNA) began a Phase 3 trial of its H5 pandemic flu vaccine candidate, mRNA-1018, dosing the first of 4,000 participants across the US and UK. The study marks a critical step in developing a rapid-response tool against a virus that health officials consider a primary pandemic threat.
"A flu pandemic is the most likely future pandemic. And it’s really critical that we ensure we’re properly prepared,” Richard Pebody, director of epidemic and emerging infections at the UK Health Security Agency, said.
The study will enroll approximately 3,000 volunteers in the UK and 1,000 in the US, prioritizing those over 65 and poultry workers who are at higher risk. Because the A(H5N1) virus is not actively circulating in people, the trial will measure the strength of the immune response as its primary endpoint, an approach supported by earlier phase studies that showed the vaccine was well-tolerated and induced a strong immune reaction.
The trial advances a key asset in Moderna's pipeline beyond Covid-19, addressing the global threat from the H5N1 clade 2.3.4.4b strain that has spread in animals. Success would validate the rapid-response advantage of mRNA technology over traditional egg-based vaccines, which are significantly slower to produce and scale.
The A(H5N1) strain has circulated globally for years, with the UK Health Security Agency noting 116 confirmed human cases worldwide since 2024, nearly all linked to contact with infected animals. While the UK holds a stockpile of 5 million conventional H5 vaccine doses, mRNA platforms allow for much faster production and modification if the virus evolves. The trial is supported by up to $54.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI).
This pandemic preparedness program runs parallel to Moderna's commercial influenza strategy. The company's seasonal flu shot, mRNA-1010, is under review by the US Food and Drug Administration with a target action date of August 5, 2026. It recently received European approval for mCOMBRIAX, its combination flu and Covid-19 vaccine.
The trial's progress is a positive signal for Moderna's efforts to diversify its revenue streams post-Covid. Investors will watch for immunogenicity data from the seven-month study as the next major catalyst for the program.
This article is for informational purposes only and does not constitute investment advice.
